2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, jco2400767. PMID: 39255440, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian follow-upPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibEvaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinomaTIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarrayGP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistryDevelopment of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC)
Kashima S, Gupta R, Moritz V, Sadak K, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC). The Oncologist 2024, 29: s5-s6. PMCID: PMC11301923, DOI: 10.1093/oncolo/oyae181.008.Peer-Reviewed Original ResearchRCC tumor microenvironmentPatient-derived tumor modelsRenal cell carcinomaImmune checkpoint inhibitorsT cell functionPeripheral blood mononuclear cellsEnzyme-linked immunosorbent assayTumor microenvironmentT cellsFlow cytometryTumor fragmentsIFN-gTumor modelTumor samplesCytokine productionHealthy donor peripheral blood mononuclear cellsImpact of immune checkpoint inhibitorsAnti-PD-1 monoclonal antibodyDonor peripheral blood mononuclear cellsCD4+CD25+ regulatory T cellsCD8+ T cell populationsResection of renal cell carcinomaSurgical resection of renal cell carcinomaAnti-PD-1 antibodyMetastatic renal cell carcinomaPathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024, 134: 596-601. PMID: 39014969, DOI: 10.1111/bju.16403.Peer-Reviewed Original ResearchPapillary renal cell carcinomaPositive predictive valueRenal cell carcinomaLocal pathology reviewCentral reviewPathology reviewCell carcinomaAdvanced papillary renal cell carcinomaMetastatic papillary renal cell carcinomaPapillary renal cell carcinoma subtypesPatients treated with targeted therapyExpert genitourinary pathologistsPathological concordance rateLocal reviewGenitourinary pathologistsClinical benefitCabozantinibClinical significanceClinical valueSubtype assignmentConcordance rateType 1CarcinomaPatientsPredictive valueCytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma
Takeda K, Adeniran A, Levi A, Tang H, Cai G. Cytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma. Cytopathology 2024 PMID: 38992916, DOI: 10.1111/cyt.13413.Peer-Reviewed Original ResearchHigh-grade papillary urothelial carcinomaLow-grade papillary urothelial carcinomaPapillary urothelial carcinomaUrothelial carcinomaVoided urine samplesCytomorphologic featuresBenign casesUrine samplesUrine specimensNuclear enlargementVoided urine specimensHigh-grade transformationNuclear-to-cytoplasmic (N/CIrregular nuclear membranesUrine cytologyRetrospective reviewHistopathological diagnosisCytomorphologic characteristicsCytomorphological distinctionFrequent recurrenceCytologic featuresCarcinomaBenign conditionsAccurate diagnosisHigh N/C ratioReevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience
Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.Peer-Reviewed Original ResearchCystic fluid cytologyFine-needle aspirationFluid cytologyAmerican College of Obstetricians and Gynecologists guidelinesSingle-institution cohortRate of malignancySurgical pathology diagnosisFNA casesGynecologists guidelinesCytological diagnosisFNA cytologyPathological diagnosisPatient demographicsInstitutional experienceSurgical pathologyOvarian cyst fluidClinical circumstancesAmerican CollegeCytologyRadiological informationMalignancyGold standardCyst fluidModerate sensitivityPotential safety concernsSarcomatoid and Rhabdoid Renal Cell Carcinoma
Adeniran A, Shuch B, Humphrey P. Sarcomatoid and Rhabdoid Renal Cell Carcinoma. The American Journal Of Surgical Pathology 2024, 48: e65-e88. PMID: 38736105, DOI: 10.1097/pas.0000000000002233.Peer-Reviewed Original ResearchRenal cell carcinomaSarcomatoid renal cell carcinomaGenomic alterationsRhabdoid differentiationRhabdoid cellsCell carcinomaWHO classification of renal tumorsClassification of renal tumorsInternational Collaboration on Cancer ReportingHistologic types of renal cell carcinomaPleomorphic undifferentiated sarcomaMalignant spindle cellsAggressive biological behaviorMolecular featuresMolecular mechanisms of tumorigenesisMechanisms of tumorigenesisSarcomatoid growthRhabdoid componentSarcomatoid componentRhabdoid featuresRenal tumorsClinical responseCollege of American PathologistsRhabdoid morphologySarcomatoid elements
2023
542 TIGIT as a potential therapeutic target in renal cell carcinoma
Kashima S, Soulati H, Madsen K, Sadak K, Wirth L, Hurwitz M, Kluger H, Sznol M, Humphrey P, Adeniran A, Kenney P, Braun D. 542 TIGIT as a potential therapeutic target in renal cell carcinoma. 2023, a616-a616. DOI: 10.1136/jitc-2023-sitc2023.0542.Peer-Reviewed Original ResearchCytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up
Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.Peer-Reviewed Original ResearchHigh-grade urothelial carcinomaLow-grade urothelial carcinomaUpper urinary tractUrothelial carcinomaUrinary tractCytologic evaluationCytology specimensInstitutional retrospective studyParis SystemHigh-grade malignancyAtypical urothelial cellsCytologic categoriesRetrospective studyInstitutional databaseCytological diagnosisUrinary cytopathologyHistopathologicMalignant cellsBenign casesUrothelial cellsTPS categoryCarcinomaReporting systemTractAUCImmune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaBrain metastasesPrimary tumorTumor microenvironmentDigital spatial profilingCell carcinomaActivation protein expressionInflammatory macrophage markersRCC brain metastasesInnate immune activatorsNormal kidney samplesProgressive stagesExtracranial metastasesTim-3Immune checkpointsImmune dysfunctionImmune activationRCC metastasisLonger survivalImmune activatorsMacrophage markersTreatment responseSeparate cohortTissue microarrayMetastatic samplesUtility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue
Sardana R, Abi‐Raad R, Adeniran A, Cai G. Utility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue. Cytopathology 2023, 34: 597-602. PMID: 37534757, DOI: 10.1111/cyt.13283.Peer-Reviewed Original ResearchConceptsParathyroid tissueFine-needle aspirationPTH casesClinicopathological characteristicsCytomorphological featuresThyroid lesionsThinPrep slidesFine needle aspiration diagnosisNeck soft tissuePatients' clinicopathological characteristicsNeedle aspiration diagnosisNegative predictive valueClinical suspicionStudy cohortPathology databaseRetrospective studyDiagnostic challengeDifferential diagnosisInstitutional experienceNeedle aspirationCytological diagnosisFNA casesAspiration diagnosisPredictive valueAdjunct testPathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.
Tripathi A, Tangen C, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Pal S, Shuch B. Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial. Journal Of Clinical Oncology 2023, 41: 4562-4562. DOI: 10.1200/jco.2023.41.16_suppl.4562.Peer-Reviewed Original ResearchProgression-free survivalPositive predictive valueCentral pathology reviewCentral reviewPathology reviewHistologic subtypeType 1PRCC subtypesAdvanced papillary renal cell carcinomaPathologic concordance rateLines of therapyPapillary renal cell carcinomaSubset of patientsType 2 tumorGreater clinical benefitRenal cell carcinomaLimited clinical valueType 2 diseaseExpert genitourinary pathologistsLocal reviewClassification of subtypesSunitinib armMET alterationsClinical outcomesClinical benefitGermline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Caulfield J, Aizenbud L, Perdigoto A, Meffre E, Jilaveanu L, Michalek D, Rich S, Aizenbud Y, Adeniran A, Herold K, Austin M, Kluger H. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer 2023, 11: e006570. PMID: 36898736, PMCID: PMC10008335, DOI: 10.1136/jitc-2022-006570.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsInsulin-dependent diabetesImmune checkpoint inhibitorsType 1 diabetesCheckpoint inhibitorsControl patientsSevere immune-related adverse eventsImmunotherapy-treated patientsCheckpoint inhibitor therapyIslet cell destructionPotential predictive biomarkersIslet cell functionWhole-exome sequencingICI exposureAdverse eventsGermline genetic variantsInhibitor therapyPatient selectionTreatment regimensCancer patientsPredictive biomarkersGeneral populationPatientsDiabetesSame drugDiagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry
Meiklejohn K, Hrones M, Wang M, Prasad M, Cai G, Adeniran A, Gilani S. Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry. Cytopathology 2023, 34: 219-224. PMID: 36825365, DOI: 10.1111/cyt.13222.Peer-Reviewed Original Research
2022
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
Schoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers In Oncology 2022, 12: 990367. PMID: 36313654, PMCID: PMC9608089, DOI: 10.3389/fonc.2022.990367.Peer-Reviewed Original ResearchRenal cell carcinomaImmune checkpoint inhibitorsMetastatic sitesBrain metastasesPrimary tumorMechanisms of resistancePD-1/PD-L1Anti-PD-1 therapyHigh-risk clinical characteristicsLarger primary tumor sizeAdvanced renal cell carcinomaAlternative immune checkpointsCertain drug regimensPoor-risk diseasePD-1 inhibitorsMinority of patientsPrimary tumor sizeLonger overall survivalGrade 4 tumorsProtein levelsPrimary RCC tumorsAttractive therapeutic targetIdentification of subgroupsCheckpoint inhibitorsUpfront therapy
2021
40. Correlation of histology, CCND1 over-expression, and CCND1 rearrangement in Renal Cell Carcinomas
Murry J, Eno C, Mendhiratta N, Ye H, Sisk A, Adeniran A, Shuch B, Kang S. 40. Correlation of histology, CCND1 over-expression, and CCND1 rearrangement in Renal Cell Carcinomas. Cancer Genetics 2021, 252: s14. DOI: 10.1016/j.cancergen.2021.01.051.Peer-Reviewed Original ResearchSunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.
Pal S, Tangen C, Thompson I, Haas N, George D, Heng D, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason G, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara P. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. Journal Of Clinical Oncology 2021, 39: 270-270. DOI: 10.1200/jco.2021.39.6_suppl.270.Peer-Reviewed Original ResearchMetastatic papillary renal cell carcinomaPapillary renal cell carcinomaProgression-free survivalMedian progression-free survivalEligible patientsPO QDPrior therapyOverall survivalAdverse eventsGrade 5 adverse eventsZubrod performance status 0Measurable metastatic diseasePerformance status 0Randomized phase IIRenal cell carcinomaMET kinase inhibitorType IMeaningful prolongationPo bidStatus 0Secondary endpointsMetastatic diseasePathologic reviewPFS eventsSystemic therapy
2020
19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
Oria V, Zhang H, Zhu H, Deng G, Zito C, Rane C, Zhang S, Weiss S, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg M, Kluger H, Jilaveanu L. 19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA. Neuro-Oncology Advances 2020, 2: ii3-ii3. PMCID: PMC7401364, DOI: 10.1093/noajnl/vdaa073.009.Peer-Reviewed Original ResearchMelanoma brain metastasesBrain metastasesTumor growthPI3K/Akt/mTORCell cycle transitionAkt/mTORGrowth of tumorsS cell cycle transitionPhosphorylation of AktMelanoma patientsPoor prognosisNovel drug targetsPatient populationRegulation of PDCD4Metastatic melanomaUnique cohortXenograft modelClinical relevanceNude miceMetastasisCycle transitionMelanomaBrain developmentKey mediatorMelanoma cells